n-3 fatty acids no benefit for high-risk cardio patients

n-3 fatty acids no benefit for high-risk cardio patients
For patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who have not had a myocardial infarction, daily treatment with n-3 fatty acids does not reduce cardiovascular mortality or morbidity, according to a study published in the May 9 issue of the New England Journal of Medicine.

(HealthDay)—For patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who have not had a myocardial infarction, daily treatment with n-3 fatty acids does not reduce cardiovascular mortality or morbidity, according to a study published in the May 9 issue of the New England Journal of Medicine.

Maria Carla Roncaglioni, Ph.D., from the Istituto di Ricerche Farmacologiche Mario Negri in Milan, and colleagues conducted a double-blind, placebo-controlled trial involving 12,513 patients with multiple or atherosclerotic vascular disease, but without myocardial infarction. Participants were randomized to receive 1 g daily n-3 fatty acids (6,244 participants) or placebo (olive oil; 6,269 participants).

With a median of five years of follow-up, the researchers found that the primary end point (cumulative rate of death, nonfatal , and nonfatal stroke) occurred in 11.8 percent of the cohort, 11.7 percent of whom had received n-3 fatty acids and 11.9 percent of whom had received placebo. Similar results were seen for all secondary end points.

"On the basis of the results, we conclude that there was no significant benefit of n-3 fatty acids in reducing the risk of death from cardiovascular causes or hospital admission for cardiovascular causes," the authors write.

The study was partially funded by Pfizer and Sigma Tau.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Fatty acids don't reduce atrial fibrillation recurrence

Dec 21, 2012

(HealthDay)—Polyunsaturated fatty acids (n-3 PUFA) do not reduce the recurrence of atrial fibrillation (AF), according to a study published online Dec. 19 in the Journal of the American College of Cardiology.

Retinopathy severity linked to cardiovascular outcome

Jan 25, 2013

(HealthDay)—For individuals with type 2 diabetes, incident cardiovascular outcomes are determined not only by the severity of diabetic retinopathy but also by its progression, according to research published ...

Recommended for you

Use of drug-eluting stents may cut in-hospital mortality

17 hours ago

(HealthDay)—Use of drug-eluting stents (DES) rather than bare-metal stents (BMS) for percutaneous coronary intervention (PCI) is associated with lower rates of in-hospital mortality, according to research ...

Gel implant might help fight heart failure

17 hours ago

(HealthDay)—Injecting beads of gel into the wall of a still-beating heart has the potential to improve the health of patients with severe heart failure, according to a new study.

Obesity fuels silent heart damage

19 hours ago

Using an ultrasensitive blood test to detect the presence of a protein that heralds heart muscle injury, researchers from Johns Hopkins and elsewhere have found that obese people without overt heart disease ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.